Serous Endometrial Carcinoma

Slide 1 · Serous Endometrial Carcinoma

Pathogenesis · Morphology · Dissemination · Clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish serous from endometrioid endometrial carcinoma.

Explain the early role of TP53 mutation and the copy-number-high phenotype.

Recognize the defining intraepithelial and invasive morphologies.

Relate transtubal/peritoneal dissemination to stage and prognosis.

Integrate histology, clinical presentation, and molecular context.

Slide 3 · The defining clinicopathologic identity

A high-grade endometrial carcinoma

Serous morphology, a strong TP53 association, and disproportionate extrauterine dissemination are its central defining attributes.

Slide 4 · Histotype frequency

≈15%

Serous endometrial carcinoma

≈80–85%

Endometrioid endometrial carcinoma

Do not read these illustrative estimates as contemporary registry rates.

Slide 5 · Serous and endometrioid: The initial contrast

Dimension

Serous

Endometrioid

Typical setting

Endometrial atrophy

Endometrial hyperplasia / estrogen-related setting

Patient age

On average ~10 years older

Relatively younger

Grade

High grade by definition

Histologic grade varies

Prominent genetic theme

TP53 alteration

PI3K/AKT-pathway alterations

Slide 6 · Endometrial atrophy is a critical context

Serous carcinoma generally arises in an atrophic endometrium.

The uterus may be small even in the presence of aggressive malignancy.

A background of estrogen-driven hyperplasia is not its characteristic pathway.

The context provides an important distinction from endometrioid carcinoma.

Atrophy is an association, not a diagnostic criterion.

Slide 7 · Age distribution is relative

Approximately a decade older

The typical patient population as about 10 years older than for endometrioid carcinoma; It does not define a diagnostic age threshold.

Slide 8 · Histotype is not synonymous with grade

Histotype

Serous: A specific morphologic entity.

Grade

All serous carcinomas are classified as high grade.

Architecture

Both papillary and glandular growth are possible.

A gland-forming serous carcinoma remains high grade.

Slide 9 · The pathogenesis can be organized causally

Early TP53 alteration

Intraepithelial neoplasia

Stromal invasion

Potential extrauterine dissemination

Conceptual order taken: The sequence is an interpretation of disease development, not a strict clock or obligatory clinical progression.

Slide 10 · TP53 is the dominant molecular association

TP53 mutated in >90%

Disruptive TP53 mutations in more than 90% of serous endometrial carcinomas.

Textbook figure; Exact value may vary by classification and contemporary cohort.

Slide 11 · How TP53 changes are represented

The affected gene is the tumor suppressor TP53.

Most mutations described are missense variants.

Altered p53 protein may accumulate in tumor-cell nuclei.

Strong, diffuse p53 immunostaining is illustrated in the Robbins figure.

This does not imply every TP53 mutation causes protein accumulation or identical IHC patterns.

Slide 12 · From genotype to protein expression

TP53 missense mutation

Altered p53 protein

Protein accumulation

Strong nuclear IHC signal

The strong diffuse pattern presented by Robbins is an example of a mutation-associated pattern, not an exhaustive p53 interpretation rule.

Illustration of accumulation mechanism specifically described in textbook Fig. 22.25B/D; No claim that all mutations yield accumulation.

Slide 13 · Timing of the TP53 alteration

An early event in tumor development

TP53 mutations are detected in noninvasive precursor lesions, supporting an early pathogenic role.

Slide 14 · Precursor confined to the epithelium

Endometrial cavity

Stroma

Basement membrane (schematic)

Schematic: Not a histologic specimen

Intraepithelial carcinoma

Severely atypical malignant cells occupy the epithelial lining without demonstrable stromal invasion.

Slide 15 · Surface-to-gland progression

Neoplastic surface lining

Extension into adjacent glands

Possible subsequent stromal invasion

Surface epithelial emergence followed by spread into adjacent gland structures before stromal invasion.

Slide 16 · Gland involvement precedes stromal invasion

Endometrial cavity

Stroma

Basement membrane (schematic)

Schematic: Not a histologic specimen

Spread along epithelial structures

Malignant epithelium may colonize adjacent glands while the epithelial–stromal boundary is preserved.

Slide 17 · Invasive carcinoma crosses into stroma

Endometrial cavity

Stroma

Basement membrane (schematic)

Schematic: Not a histologic specimen

Stromal invasion

Invasion implies neoplastic cells beyond the glandular epithelial boundary into the underlying endometrial stroma.

Slide 18 · Two distinct morphologic states

Finding

Intraepithelial carcinoma

Invasive serous carcinoma

Cells

High-grade malignant cytology

High-grade malignant cytology

Location

Surface/gland epithelial lining

May extend into endometrial stroma

Stromal infiltration

Not demonstrated

Present

Clinical implication

Cannot assume biologic indolence

May have direct invasion and systemic spread

Slide 19 · Genomic instability is a major feature

Serous carcinomas commonly have considerable chromosomal instability.

Numerous somatic copy-number alterations are typical.

These findings are additional to point mutations.

The genomic phenotype corresponds closely to the copy-number-high category.

Slide 20 · Four molecular categories

POLE

Ultramutated: Exceptional somatic mutation burden.

MMR / MSI

Hypermutated: Mismatch repair defects.

Copy-number low

Nonspecific molecular phenotype; Frequent in endometrioid tumors.

Copy-number high

TP53-mutated; Serous or high-grade endometrioid morphology.

Molecular classes as pp. 915–916; These are not histologic synonyms.

Slide 21 · Serous histology versus molecular class

Related—but not identical—axes

The copy-number-high/TP53-mutated category contains serous and some high-grade endometrioid tumors. Do not equate the class exclusively with serous histology.

Slide 22 · Molecular class and typical pathology

Molecular category

Defining context in Robbins

Important interpretive limit

POLE ultramutated

POLE proofreading mutation

Mutation burden is not inferred from serous morphology

MSI hypermutated

Mismatch repair defect

Histotype alone cannot assign this category

Copy-number low

Often endometrioid, PI3K/AKT related

Not equivalent to all endometrioid tumors

Copy-number high

TP53 mutation and many CN alterations

Includes serous and high-grade endometrioid

Slide 23 · The genetic and morphological evidence converge

Early TP53 variant

High-grade malignant epithelium

Genomically unstable invasive tumor

The association is strong; The sequence is simplified for teaching and does not imply that TP53 alone produces every observed feature.

Slide 24 · Macroscopic setting

Small, atrophic uterus

The characteristic background may be atrophic even when tumor burden and biologic aggressiveness are considerable.

Slide 25 · Three gross-pattern lessons

Background uterus

Often small and atrophic.

Visible lesion

May form a large, bulky endometrial mass.

Depth

Can infiltrate deeply into myometrium.

Slide 26 · Myometrial invasion is not uniform

A subset of tumors invades deeply into the myometrium.

Other cases exhibit relatively superficial uterine involvement.

The extent of uterine-wall invasion alone may underestimate extrauterine disease.

Stage assessment therefore cannot rely on apparent uterine bulk.

Slide 27 · Microscopic architecture is variable

Papillary architecture

High-grade malignant cytology

Diagnosis of serous carcinoma

Papillary growth is characteristic, but not required: A predominantly glandular architecture may occur.

Slide 28 · Papillary growth is a frequent pattern

Malignant papillary structures

Papillary lesions populated by cells with marked cytologic atypia, including hyperchromasia, atypical mitoses, and prominent nucleoli.

Slide 29 · Atypia is multidimensional

Nuclear-to-cytoplasmic ratio

A relatively large nucleus compared with cytoplasm.

Hyperchromasia

Darkly staining nuclei reflect increased/abnormal chromatin.

Prominent nucleoli

Conspicuous nuclear substructures.

Atypical mitoses

Abnormal mitotic figures accompanying high grade.

Slide 30 · High nuclear-to-cytoplasmic ratio

The nucleus occupies a large fraction of the tumor-cell profile.

This feature contributes to a high-grade cytologic impression.

It must be interpreted alongside chromatin, mitoses, and architecture.

It is not specific in isolation for serous histotype.

Slide 31 · Hyperchromasia and pleomorphism

Hyperchromatic nuclei are explicitly.

Marked cytologic atypia is present even in gland-forming areas.

Nuclear findings distinguish high-grade serous carcinoma from well-formed low-grade glands.

Architecture should not override the atypia assessment.

Slide 32 · Prominent nucleoli and atypical mitoses

Conspicuous nucleoli are part of the high-grade cytologic spectrum.

Atypical mitotic figures support malignant proliferative activity.

These findings are interpreted in the context of epithelial neoplasia.

Neither feature alone is pathognomonic of serous carcinoma.

Slide 33 · Architectural grade does not down-grade serous cancer

All serous tumors are high grade

A serous carcinoma with a predominantly glandular growth pattern remains classified as high grade irrespective of the proportion of solid growth.

Slide 34 · Why the gland-forming differential is difficult

Observation

Serous carcinoma

Endometrioid carcinoma

Glandular pattern

Possible despite high-grade histology

Common and often dominant

High-grade nuclei

Marked, even in well-formed glands

Depends on tumor grade

Most prominent pathway

TP53 alteration

PI3K/AKT-pathway alterations

Usual context

Atrophic endometrium

Hyperplasia/estrogen-associated

Slide 35 · A disciplined morphologic reading sequence

Locate the neoplastic epithelium

Assess cytologic grade

Evaluate architecture

Seek stromal invasion

Avoid assigning serous histotype solely from a papillary shape or from a p53 result.

Slide 36 · Interpretation of p53 staining

The textbook figure shows strong diffuse nuclear staining in precursor and invasive components.

Protein accumulation is linked to many missense TP53 mutations.

Immunostaining is supportive when paired with high-grade morphology.

Robbins does not provide a complete p53-IHC diagnostic algorithm in this excerpt.

No wild-type/overexpression/null/cytoplasmic thresholds are asserted; Outside classification validation would be required.

Slide 37 · Intraepithelial disease is still high grade

Malignant cytology without stromal invasion

The absence of invasion defines the morphologic compartment, not necessarily an absence of dissemination potential.

Slide 38 · Boundary is the decisive feature

Endometrial cavity

Stroma

Basement membrane (schematic)

Schematic: Not a histologic specimen

Invasion versus epithelial replacement

The diagnostically relevant question is whether malignant cells extend beyond epithelial surfaces into stroma.

Slide 39 · Histologic sampling must answer distinct questions

Is high-grade malignant epithelium present?

Does it merely line pre-existing endometrial glands?

Is there demonstrated stromal or myometrial invasion?

Does the sampled pattern support serous rather than another histotype?

Can the findings be integrated with clinical stage?

Slide 40 · Why extrauterine disease can appear early

Endometrial malignant epithelium

Tumor-cell exfoliation

Transtubal transit

Peritoneal implantation

Trans-tubal dissemination as a major explanation for extensive peritoneal involvement, even with superficial uterine disease.

Slide 41 · Exfoliation is a biologic bridge

Tumor cells separate from the surface

Surface-exposed malignant cells may enter the uterine cavity; The proposed route continues through fallopian tubes to peritoneal surfaces.

Slide 42 · Two broad routes of spread

Lymphatic dissemination

Extrauterine deposits

Advanced stage at diagnosis

This is one of the spread mechanisms identified by Robbins; Transtubal/peritoneal dissemination is separately important.

Slide 43 · Patterns of dissemination described

Route

Anatomic logic

Interpretive consequence

Direct local invasion

Tumor extends through adjacent uterine wall

Depth of invasion can be observed in tissue

Transtubal/peritoneal

Exfoliated cells traverse tubes and implant

Superficial uterine disease may coexist with peritoneal deposits

Lymphatic

Tumor disseminates via lymphatic channels

Extrauterine spread contributes to stage

Slide 44 · A crucial clinicopathologic paradox

Superficial primary ≠ localized disease

That limited endometrial involvement may coexist with extensive peritoneal disease.

Slide 45 · Why stage dominates outcome

Morphology

High-grade disease has aggressive potential.

Extent

Extrauterine deposits alter the actual disease burden.

Prognosis

Anatomic stage is a major determinant of survival.

Slide 46 · Clinical presentation

Endometrial carcinoma commonly produces abnormal uterine bleeding.

Postmenopausal bleeding is a characteristic clinical trigger for evaluation.

Some tumors may be asymptomatic for a period.

Bleeding alone cannot establish the histologic subtype.

Slide 47 · From bleeding to pathologic diagnosis

Abnormal/postmenopausal bleeding

Endometrial tissue sampling

Microscopic assessment

Diagnosis of subtype and invasion

Diagnosis requires histologic examination of biopsy or curettage tissue.

Slide 48 · There is no established population screening test

Symptom-led investigation

No available screening test for endometrial carcinoma; Diagnostic workup requires tissue once suspicion is raised.

Slide 49 · Why a biopsy can be limited

A biopsy samples only part of the endometrial lesion.

A high-grade epithelial lesion may be represented by scant fragments.

Histology establishes carcinoma; Full anatomic extent requires additional assessment.

Superficial sampling cannot by itself exclude extrauterine dissemination.

The sampling limitation is a logical implication of the anatomical source description; Not a quantified sensitivity claim.

Slide 50 · Anatomical stage: Simplified Robbins schema

Stage

Anatomic extent in textbook

I

Carcinoma confined to uterine corpus

II

Involves uterine corpus and cervical stroma

III

Beyond uterus but not outside true pelvis

IV

Beyond true pelvis or bladder/rectal mucosa

This is the textbook simplified staging summary, NOT claimed to be a current FIGO 2023/2026 staging reference. Clinical staging should use the applicable official FIGO edition.

Slide 51 · Stage and histotype provide different information

Stage = extent; Histotype = biological category

A serous tumor may have aggressive biology, but anatomical spread remains a major determinant of prognosis.

Slide 52 · Outcome figures reported

18–27%

Overall 5-year survival quoted for serous carcinoma

Up to 80%

Recurrence quoted even for uterus-confined tumors

These are figures from the Robbins 11th-edition narrative; They are not new cohort estimates and should not be used for individual prediction.

Historical/heterogeneous outcome statistics as published. No original cohort, calendar period, stratification or contemporary therapy validation supplied.

Slide 53 · Interpret outcome figures carefully

Survival and recurrence estimates depend on patient selection and stage.

Treatment era and molecular subclassification may affect outcomes.

The textbook figures summarize a particularly aggressive histotype.

They must not be presented as an individualized probability.

Interpretation caution; No new numeric outcomes added.

Slide 54 · Clinical risk cannot be inferred from uterine size

A small uterus is not reassuring

An atrophic uterus or superficially involved endometrium does not exclude lymphatic or peritoneal spread.

Slide 55 · Therapeutic contrast reported by Robbins

Context

General treatment implication described

Endometrioid carcinoma

Surgery ± radiation; chemotherapy frequently when beyond uterus

Serous carcinoma

Chemotherapy may be considered despite no detectable extrauterine disease

Molecularly selected disease

Checkpoint inhibitors associated with MSI / POLE molecular categories

HER2-amplified subset

HER2-directed approaches discussed as developing strategy

Do not interpret as a current prescriptive treatment protocol; Textbook-level overview.

Slide 56 · Serous histology changes adjuvant discussions

Aggressive even when grossly limited

Consideration of chemotherapy in serous carcinoma without demonstrable extrauterine extension.

Slide 57 · HER2 amplification: Precise denominator

25–30%

Up to this proportion of ENDOMETRIAL carcinomas in the cited text

HER2 amplification is seen predominantly in TP53-mutated tumors. The percentage is not stated as a serous-only rate.

Do not misreport percentage as HER2-positive uterine serous carcinoma prevalence. Treatment selection requires current validated testing guidance.

Slide 58 · Integrating modern biomarkers conservatively

Histologic serous subtype and molecular class are related but distinct.

TP53 alteration is highly characteristic, not the sole possible driver.

The HER2 observation concerns a subset of endometrial cancers.

A current molecular treatment protocol cannot be derived from this excerpt alone.

Slide 59 · Case application: Atrophic uterus

A postmenopausal patient has bleeding. A biopsy shows severely atypical epithelium in atrophic endometrium.

A. Exclude cancer because the endometrium is atrophic

B. Consider high-grade serous carcinoma and assess invasion

C. Call it low-grade endometrioid carcinoma based only on glands

Interpretation: B — serous carcinoma must be considered

Atrophy plus malignant nuclear features is consistent with the Robbins serous carcinoma setting.

Slide 60 · Case application: Glandular high-grade lesion

Endometrial glands are lined by cells with marked hyperchromasia, high N:C ratio, and atypical mitoses.

A. Gland formation excludes serous carcinoma

B. Architecture automatically establishes low grade

C. Serous carcinoma remains possible despite glandular growth

Interpretation: C — nuclear grade remains decisive

Robbins explicitly describes a glandular-predominant serous growth pattern.

Slide 61 · Case application: Epithelial-limited lesion

Markedly malignant epithelium lines endometrial glands; Stromal infiltration is not demonstrable in the section.

A. Endometrial intraepithelial carcinoma

B. Deeply invasive serous carcinoma by definition

C. Benign endometrial hyperplasia

Interpretation: A — intraepithelial morphology

The precursor described in Fig. 22.25A is confined to the epithelial lining.

Slide 62 · Case application: Limited uterine involvement

Hysterectomy shows superficially involved endometrium, but abdominal evaluation identifies peritoneal deposits.

A. The findings are incompatible

B. Possible transtubal/peritoneal dissemination

C. Invasion cannot be associated with metastasis

Interpretation: B — a recognized dissemination pattern

Peritoneal disease despite superficial endometrial involvement.

Slide 63 · Case application: P53 interpretation

A tumor displays severe nuclear atypia and strong diffuse nuclear p53 immunostaining.

A. The two findings support the TP53-associated serous pattern

B. The stain alone proves a specific TP53 variant

C. Normal p53 protein function is thereby established

Interpretation: A — interpret in morphological context

Strong staining is an example shown by Robbins and not a comprehensive mutation-test substitute.

Slide 64 · A practical pathology interpretation pathway

Identify high-grade atypical epithelium

Characterize papillary or glandular patterns

Evaluate epithelial/stromal interface

Integrate spread and stage

Molecular information, including TP53/p53, is supportive; The source does not provide a definitive integrated laboratory algorithm.

Slide 65 · Five conclusions to retain

Serous carcinoma is intrinsically high grade and usually occurs with endometrial atrophy.

TP53 mutations are found in more than 90% account.

Endometrial intraepithelial carcinoma has malignant cells without stromal invasion.

Glandular architecture does not preclude serous histotype.

Early extrauterine spread explains its poor prognosis.

Slide 66 · Sources and interpretive boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease

11th edition (2026), Chapter 22, The Female Genital Tract, pp. 915–919

Primary section: “Serous Endometrial Carcinoma,” pp. 918–919.

Parent context: molecular subtypes of endometrial carcinoma and comparison with endometrioid carcinoma, pp. 915–918.

Original editable PowerPoint diagrams; no synthetic specimen images, invented cohorts, or copied textbook illustrations.